<DOC>
	<DOCNO>NCT00998049</DOCNO>
	<brief_summary>Rationale : Giving colony-stimulating factor , G-CSF plerixafor help stem cell move patient 's bone marrow blood collect store . Purpose : This phase II trial study well plerixafor work patient multiple myeloma previously treat lenalidomide planning undergo autologous stem cell transplant .</brief_summary>
	<brief_title>Plerixafor Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide Planning Undergo Autologous Stem Cell Transplant</brief_title>
	<detailed_description>Primary Objective : I . To determine proportion patient reach stem cell yield 3 million CD34 cells/kg second day apheresis intravenously administer AMD3100 among patient receive primary therapy myeloma lenalidomide . Secondary Objectives : I . Safety tolerability intravenously administer AMD3100 . II . Rate failure mobilize . Outline : Patients receive plerixafor IV day 5-8 filgrastim subcutaneously day 1-8 absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>Inclusion Absolute neutrophil count &gt; = 1000/uL Platelet &gt; = 75000/uL Hemoglobin &gt; = 8.0 g/dL Serum aspartate aminotransferase ( AST ) /serum glutamic oxaloacetic transaminase ( SGOT ) , serum alanine aminotransferase ( ALT ) /serum glutamic pyruvic transaminase ( SGPT ) total bilirubin &lt; 2 x upper limit normal ( ULN ) Confirmed diagnosis multiple myeloma , require therapy Initial treatment symptomatic myeloma use lenalidomide base treatment regimen , start = &lt; 12 month prior registration Received least 2 cycle treatment lenalidomide regimen Last dose lenalidomide &gt; 2 week prior registration Eligible undergo autologous transplantation ECOG performance status ( PS ) 0 1 Willingness return followup Provide inform write consent Adequate cardiopulmonary function : ejection fraction &gt; = 45 % , correct pulmonary diffusion capacity &gt; = 50 % , FEV1 &gt; = 50 % , FVC &gt; = 50 % Negative serum urine pregnancy test do = &lt; 7 day prior registration , woman childbearing potential Exclusion A comorbid condition , view Investigators , render patient high risk treatment complication Active malignancy exception non melanoma skin cancer situ cervical breast cancer Other comorbidity would interfere patient 's ability participate trial , e.g . uncontrolled infection , uncompensated heart lung disease Other concurrent chemotherapy , radiotherapy , ancillary therapy consider investigational Use cyclophosphamide part stem cell mobilization Use one regimen treatment symptomatic myeloma Dialysis dependent renal failure Pregnant woman woman reproductive ability unwilling use effective contraception Nursing woman Men unwilling use condom ( even undergone prior vasectomy ) intercourse woman , take drug 4 week stop treatment Acute infection , active HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>